In a welcome move, Ligand Pharmaceuticals saw its Relative Strength Rating improve from 69 to 79 on Thursday.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the best stocks often have an 80 or higher RS Rating in the early stages of their moves. See if Ligand Pharmaceuticals can continue to rebound and hit that benchmark.
Ligand Pharmaceuticals is trying to complete a consolidation with a 129.90 buy point. See if it can clear the breakout price in heavy volume. Be aware that it's a third-stage base. Later-stage patterns can work, but have a higher chance of failing since, by that point, the stock has already climbed substantially..
Ligand Pharmaceuticals reported -65% EPS growth in its most recent report. Sales gains came in at 46%.
The company earns the No. 25 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
